The TETON programme consisted of two replicate, 52-week, randomised, double-blind, placebo-controlled, phase 3 studies, investigating inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis (NCT04708782, NCT05255991). touchRESPIRATORY were delighted to talk with Dr. Steven D. Nathan (Inova Fairfax Hospital, Annandale, VA, USA) to discuss the aims, design, eligibility criteria and endpoints being investigated in the TETON […]